U Rwanda Rugiye Gushora Miliyari 107 Frw Mu Gukingira COVID-19

Minisiteri y’Imari n’Igenamigambi igaragaza ko mu ngengo y’imari y’umwaka wa 2021/22 hateganyijwemo miliyari 107.7 Frw, zizashyirwa mu mushinga wo gukingira icyorezo cya COVID-19 mu gihugu.

Ni kimwe mu bikorwa binini byateganyijwe mu ngengo y’imari y’umwaka utaha, mu nkingi yo guteza imbere imibereho myiza. Minisitiri Dr Uzziel Ndagijimana yayigejeje ku Nteko Ishinga Amategeko ku wa Kabiri.

Mu ngengo y’imari yose hamwe ya miliyari 3807, ibikorwa bikubiye muri iki cyiciro byagenewe miliyari 1034.3 bingana na 27.2% by’ingengo y’imari yose.

Guverinoma y’u Rwanda iheruka gutangaza ko ifite intego yo gukingira abaturage 60% mbere y’uko umwaka wa 2022 urangira, ni ukuvuga nibura abaturage miliyoni 7.8.

- Kwmamaza -

Ni igikorwa byatangajwe ko kizatwara miliyoni 124$ (arenga miliyari 123 Frw) yo kugura, kubika, gukwirakwiza ndetse no kuzitera abaturage muri rusange.

Guverinoma ihanganye n’izamuka rikabije ry’ubwandu bwa COVID-19 ndetse n’abaremba bakajyanwa kuvurirwa mu bitaro, biyongereye cyane kuva mu minsi ishize. Impamvu nyamukuru ni ukudohoka kwa benshi ku mabwiriza yo kwirinda.

Mu butumwa yasohoye kuri uyu wa Gatatu, Minisitiri w’Ubuzima Dr Ngamije Daniel yagize ati “Leta y’u Rwanda irakora ibishoboka byose kugira ngo urukingo rugere ku baturarwanda benshi bashoboka, nibura 60% y’abanyarwanda.”

Mu Rwanda hamaze gukingirwa 391,058 hakoreshejwe inkingo za AstraZeneca na Pfizer.

Dr Ngamije aheruka kuvuga ko kugeza mu mpera z’uyu mwaka u Rwanda ruzakira inkingo miliyoni 3.5 za COVID-19 zo mu bwoko bwa Pfizer- BioNTech, zisanga izindi nyinshi za AstraZeneca.

Ati “Hari inkingo dutegereje mbere y’uko umwaka urangira, izindi tuzazibona mu mpera z’ukwezi kwa gatandatu nanone ni iza Pfizer, ku buryo kugeza mu mpera z’uyu mwaka mu kwezi kwa 12, twiteguye kwakira izindi nkingo miliyoni 3.5 za Pfizer.”

Nubwo inkingo zirimo gutangwa zitarinda abantu kwandura COVID-19, zibarinda kuremba ku gipimo cya 100%.

 

Share This Article
Tanga igitekerezo

Leave a Reply

Your email address will not be published. Required fields are marked *

Exit mobile version